Iovance
ShareCopied to clipboardIovance is a company. It is a public company in San Carlos, the United States. It was founded in 2007 and its current CEO is Frederick G. Vogt. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: San Carlos
- country: United States
- employees: 838 people
- revenues: 164.1M $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 2007
- CEO: Frederick G. Vogt
- CEO approval: 81 %
- ESG score: 69.43 / 100
See more facts
Extract data
Download datasets about Iovance:
Dataset of stocks from Iovance:
Iovance is one of the companies in the United States, companies in Biotechnology, companies in Health Care, companies in San Carlos and 3,456,808 companies in our database.
Talking Points
- Investigating TIL Therapy & PBL Therapy for Cancer - Iovance Biotherapeutics
- Learn about our investigational tumor infiltrating lymphocyte (TIL) therapy and peripheral blood lymphocyte (PBL) therapy. View our clinical trials and pipeline.
- Iovance Biotherapeutics is dedicated to the fight against cancer.
- Iovance Biotherapeutics (NASDAQ: IOVA) is dedicated to the fight against cancer. | Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient's own immune cells to attack cancer.
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.